Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2018-02-14 Declaration of Voting R…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections detailing the 'Notification of Major Holdings' as per German Securities Trading Act (WpHG). It reports changes in voting rights percentages (e.g., from 10.92% to 0.001%) held by Bank of America Corporation in STADA Arzneimittel AG. This directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns best with the Major Shareholding Notification (MRQ) category. Although the header mentions 'Voting Rights Announcements', the content structure is a formal notification of a change in a major holding threshold crossing.
2018-02-14 English
STADA Arzneimittel AG:
M&A Activity Classification · 99% confidence The document text explicitly mentions an 'Extraordinary General Meeting of STADA Arzneimittel AG' and details the approval of a 'domination and profit and loss transfer agreement (DPLTA)' during this meeting. This content directly relates to the proceedings and outcomes of a shareholder meeting, specifically concerning corporate governance and major structural agreements approved by shareholders. While it is an announcement about the meeting's outcome, the core subject matter is the result of a shareholder vote on a significant corporate action, which aligns closely with the scope of AGM-R (AGM Information) or DVA (Declaration of Voting Results & Voting Rights Announcements). Since the text focuses on the approval of a major agreement during the EGM, AGM-R is the most appropriate primary classification for materials related to the meeting itself, even if it's reporting the result. Given the context of an Extraordinary General Meeting (EGM) approval, AGM-R is selected over DVA, which is typically for the formal declaration of voting results after the fact, although there is overlap. The document is a news release announcing the outcome of the meeting.
2018-02-02 English
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018
Board/Management Information Classification · 100% confidence The document is a short news release dated February 1, 2018, announcing a specific change in senior management: the appointment of Peter Goldschmidt as the new Chairman of the Executive Board, effective September 1, 2018. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is brief and serves as an immediate disclosure, not a comprehensive report.
2018-02-01 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Acquisition/disposal of shares with voting rights' and the 'Total positions' of voting rights held by Mr. Paul E. Singer and associated entities (Cornwall (Luxembourg) S.à r.l., etc.). This directly corresponds to the definition of a notification of changes in significant share ownership levels or voting rights, which maps to the 'Major Shareholding Notification' (MRQ) or potentially 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Since the content focuses on the notification of a change in voting rights percentage (15.24% resulting situation vs. 15.24% previous notification, with a change in breakdown), and the header explicitly mentions 'Voting Rights Announcements', MRQ is the most precise fit for tracking major shareholder changes, although DVA is also related to voting. Given the context of tracking ownership thresholds (WpHG Article 40), MRQ is the standard classification for this type of filing.
2018-01-29 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, specifically 'Notification of Major Holdings' under German securities law (WpHG). Section 6 details the 'Total positions' regarding the percentage of voting rights attached to shares and instruments. This content directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. Therefore, the appropriate code is MRQ.
2018-01-22 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in voting rights percentages (0.35% direct, 10.56% via instruments) held by Bank of America Corporation in STADA Arzneimittel AG, crossing specific thresholds. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2018-01-22 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.